These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37542300)

  • 1. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.
    Hagenacker T; Maggi L; Coratti G; Youn B; Raynaud S; Paradis AD; Mercuri E
    Neurol Ther; 2024 Oct; 13(5):1483-1504. PubMed ID: 39222296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China.
    Li D; Yang J; Wang X; Yang L; Luo R; Huang S
    Brain Behav; 2024 Jul; 14(7):e3630. PubMed ID: 39034388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study.
    Gallone A; Mazzi F; Bonanno S; Zanin R; Moscatelli M; Aquino D; Maggi L
    Acta Myol; 2022 Jun; 41(2):76-83. PubMed ID: 35832502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study.
    Yoon JA; Jeong Y; Lee J; Lee DJ; Lee KN; Shin YB
    BMC Neurol; 2024 Jun; 24(1):210. PubMed ID: 38902631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.